nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A3—coronary artery disease	0.275	1	CbGaD
Methamphetamine—Nateglinide—Trandolapril—coronary artery disease	0.0528	0.129	CrCrCtD
Methamphetamine—Nateglinide—Enalapril—coronary artery disease	0.0528	0.129	CrCrCtD
Methamphetamine—Aspartame—Trandolapril—coronary artery disease	0.0502	0.122	CrCrCtD
Methamphetamine—Aspartame—Enalapril—coronary artery disease	0.0502	0.122	CrCrCtD
Methamphetamine—Lisdexamfetamine—Lisinopril—coronary artery disease	0.0464	0.113	CrCrCtD
Methamphetamine—SLC22A5—Niacin—coronary artery disease	0.046	0.329	CbGbCtD
Methamphetamine—Nateglinide—Lisinopril—coronary artery disease	0.0413	0.101	CrCrCtD
Methamphetamine—Nateglinide—Ramipril—coronary artery disease	0.04	0.0974	CrCrCtD
Methamphetamine—Aspartame—Lisinopril—coronary artery disease	0.0393	0.0955	CrCrCtD
Methamphetamine—Aspartame—Ramipril—coronary artery disease	0.038	0.0925	CrCrCtD
Methamphetamine—SLC22A5—Furosemide—coronary artery disease	0.0302	0.216	CbGbCtD
Methamphetamine—CYP2D6—Niacin—coronary artery disease	0.011	0.0786	CbGbCtD
Methamphetamine—CYP2D6—Timolol—coronary artery disease	0.0102	0.0731	CbGbCtD
Methamphetamine—CYP2D6—Captopril—coronary artery disease	0.009	0.0643	CbGbCtD
Methamphetamine—CYP2D6—Simvastatin—coronary artery disease	0.00869	0.0621	CbGbCtD
Methamphetamine—CYP2D6—Lovastatin—coronary artery disease	0.00851	0.0608	CbGbCtD
Methamphetamine—CYP2D6—Pravastatin—coronary artery disease	0.00851	0.0608	CbGbCtD
Methamphetamine—CYP2D6—Atorvastatin—coronary artery disease	0.00775	0.0554	CbGbCtD
Methamphetamine—SLC6A2—sympathetic nervous system—coronary artery disease	0.0013	0.183	CbGeAlD
Methamphetamine—SLC6A2—autonomic nervous system—coronary artery disease	0.000876	0.123	CbGeAlD
Methamphetamine—Phenformin—KCNJ8—coronary artery disease	0.000666	0.226	CrCbGaD
Methamphetamine—Tolazoline—HRH2—coronary artery disease	0.000473	0.161	CrCbGaD
Methamphetamine—Erectile dysfunction—Trandolapril—coronary artery disease	0.000417	0.00589	CcSEcCtD
Methamphetamine—Erectile dysfunction—Enalapril—coronary artery disease	0.000415	0.00587	CcSEcCtD
Methamphetamine—Erectile dysfunction—Telmisartan—coronary artery disease	0.000409	0.00579	CcSEcCtD
Methamphetamine—Diarrhoea—Pitavastatin—coronary artery disease	0.000406	0.00574	CcSEcCtD
Methamphetamine—Agitation—Acetylsalicylic acid—coronary artery disease	0.000404	0.00572	CcSEcCtD
Methamphetamine—Erectile dysfunction—Captopril—coronary artery disease	0.000398	0.00563	CcSEcCtD
Methamphetamine—Dizziness—Pitavastatin—coronary artery disease	0.000393	0.00555	CcSEcCtD
Methamphetamine—Erectile dysfunction—Perindopril—coronary artery disease	0.000387	0.00546	CcSEcCtD
Methamphetamine—Headache—Pitavastatin—coronary artery disease	0.000372	0.00526	CcSEcCtD
Methamphetamine—Dyspepsia—Gemfibrozil—coronary artery disease	0.00037	0.00523	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Gemfibrozil—coronary artery disease	0.000363	0.00513	CcSEcCtD
Methamphetamine—Erectile dysfunction—Losartan—coronary artery disease	0.000363	0.00513	CcSEcCtD
Methamphetamine—Dyspepsia—Ticagrelor—coronary artery disease	0.000362	0.00511	CcSEcCtD
Methamphetamine—Tremor—Lovastatin—coronary artery disease	0.00036	0.00509	CcSEcCtD
Methamphetamine—Constipation—Gemfibrozil—coronary artery disease	0.00036	0.00508	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Ticagrelor—coronary artery disease	0.000355	0.00501	CcSEcCtD
Methamphetamine—Constipation—Ticagrelor—coronary artery disease	0.000351	0.00497	CcSEcCtD
Methamphetamine—Tachycardia—Acetylsalicylic acid—coronary artery disease	0.000351	0.00496	CcSEcCtD
Methamphetamine—Palpitations—Fenofibrate—coronary artery disease	0.000347	0.00491	CcSEcCtD
Methamphetamine—Lacosamide—CA5B—coronary artery disease	0.000346	0.117	CrCbGaD
Methamphetamine—Palpitations—Clopidogrel—coronary artery disease	0.000342	0.00483	CcSEcCtD
Methamphetamine—Diarrhoea—Penbutolol—coronary artery disease	0.000337	0.00477	CcSEcCtD
Methamphetamine—Tremor—Simvastatin—coronary artery disease	0.000336	0.00476	CcSEcCtD
Methamphetamine—Insomnia—Rosuvastatin—coronary artery disease	0.000334	0.00473	CcSEcCtD
Methamphetamine—Urticaria—Gemfibrozil—coronary artery disease	0.000334	0.00472	CcSEcCtD
Methamphetamine—Palpitations—Ezetimibe—coronary artery disease	0.000333	0.0047	CcSEcCtD
Methamphetamine—Dizziness—Penbutolol—coronary artery disease	0.000326	0.00461	CcSEcCtD
Methamphetamine—Dyspepsia—Rosuvastatin—coronary artery disease	0.000325	0.0046	CcSEcCtD
Methamphetamine—Dyspepsia—Acetylsalicylic acid—coronary artery disease	0.000316	0.00447	CcSEcCtD
Methamphetamine—Constipation—Rosuvastatin—coronary artery disease	0.000316	0.00447	CcSEcCtD
Methamphetamine—Tachycardia—Fenofibrate—coronary artery disease	0.000313	0.00443	CcSEcCtD
Methamphetamine—Erectile dysfunction—Ramipril—coronary artery disease	0.000311	0.00439	CcSEcCtD
Methamphetamine—Agitation—Olmesartan—coronary artery disease	0.00031	0.00438	CcSEcCtD
Methamphetamine—Headache—Penbutolol—coronary artery disease	0.000309	0.00436	CcSEcCtD
Methamphetamine—Tremor—Pravastatin—coronary artery disease	0.000304	0.0043	CcSEcCtD
Methamphetamine—Erectile dysfunction—Timolol—coronary artery disease	0.000304	0.0043	CcSEcCtD
Methamphetamine—Hypersensitivity—Ticagrelor—coronary artery disease	0.000303	0.00428	CcSEcCtD
Methamphetamine—MAOB—cardiac ventricle—coronary artery disease	0.000301	0.0423	CbGeAlD
Methamphetamine—Palpitations—Valsartan—coronary artery disease	0.0003	0.00424	CcSEcCtD
Methamphetamine—Palpitations—Olmesartan—coronary artery disease	0.000298	0.00422	CcSEcCtD
Methamphetamine—Tremor—Enalapril—coronary artery disease	0.000294	0.00416	CcSEcCtD
Methamphetamine—Urticaria—Rosuvastatin—coronary artery disease	0.000294	0.00415	CcSEcCtD
Methamphetamine—Palpitations—Niacin—coronary artery disease	0.000291	0.00412	CcSEcCtD
Methamphetamine—Insomnia—Fenofibrate—coronary artery disease	0.00029	0.0041	CcSEcCtD
Methamphetamine—Agitation—Trandolapril—coronary artery disease	0.00029	0.0041	CcSEcCtD
Methamphetamine—Agitation—Enalapril—coronary artery disease	0.000289	0.00408	CcSEcCtD
Methamphetamine—Diarrhoea—Gemfibrozil—coronary artery disease	0.000288	0.00407	CcSEcCtD
Methamphetamine—Urticaria—Acetylsalicylic acid—coronary artery disease	0.000285	0.00403	CcSEcCtD
Methamphetamine—Insomnia—Clopidogrel—coronary artery disease	0.000285	0.00403	CcSEcCtD
Methamphetamine—Insomnia—Lovastatin—coronary artery disease	0.000283	0.00401	CcSEcCtD
Methamphetamine—MAOB—myocardium—coronary artery disease	0.000283	0.0398	CbGeAlD
Methamphetamine—Dyspepsia—Fenofibrate—coronary artery disease	0.000282	0.00399	CcSEcCtD
Methamphetamine—Erectile dysfunction—Lisinopril—coronary artery disease	0.000282	0.00399	CcSEcCtD
Methamphetamine—Diarrhoea—Ticagrelor—coronary artery disease	0.000281	0.00397	CcSEcCtD
Methamphetamine—Palpitations—Trandolapril—coronary artery disease	0.000279	0.00394	CcSEcCtD
Methamphetamine—Dizziness—Gemfibrozil—coronary artery disease	0.000278	0.00393	CcSEcCtD
Methamphetamine—Insomnia—Ezetimibe—coronary artery disease	0.000278	0.00393	CcSEcCtD
Methamphetamine—Dyspepsia—Clopidogrel—coronary artery disease	0.000278	0.00393	CcSEcCtD
Methamphetamine—Palpitations—Enalapril—coronary artery disease	0.000278	0.00392	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Fenofibrate—coronary artery disease	0.000277	0.00392	CcSEcCtD
Methamphetamine—Dyspepsia—Lovastatin—coronary artery disease	0.000276	0.0039	CcSEcCtD
Methamphetamine—Constipation—Fenofibrate—coronary artery disease	0.000274	0.00388	CcSEcCtD
Methamphetamine—Tremor—Perindopril—coronary artery disease	0.000274	0.00387	CcSEcCtD
Methamphetamine—Palpitations—Telmisartan—coronary artery disease	0.000274	0.00387	CcSEcCtD
Methamphetamine—Hypersensitivity—Rosuvastatin—coronary artery disease	0.000272	0.00385	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Clopidogrel—coronary artery disease	0.000272	0.00385	CcSEcCtD
Methamphetamine—Insomnia—Eplerenone—coronary artery disease	0.000272	0.00385	CcSEcCtD
Methamphetamine—Dizziness—Ticagrelor—coronary artery disease	0.000272	0.00384	CcSEcCtD
Methamphetamine—Dyspepsia—Ezetimibe—coronary artery disease	0.000271	0.00382	CcSEcCtD
Methamphetamine—Constipation—Clopidogrel—coronary artery disease	0.00027	0.00381	CcSEcCtD
Methamphetamine—Tachycardia—Olmesartan—coronary artery disease	0.000269	0.0038	CcSEcCtD
Methamphetamine—Agitation—Perindopril—coronary artery disease	0.000269	0.0038	CcSEcCtD
Methamphetamine—Constipation—Lovastatin—coronary artery disease	0.000268	0.00379	CcSEcCtD
Methamphetamine—Palpitations—Captopril—coronary artery disease	0.000266	0.00376	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Ezetimibe—coronary artery disease	0.000265	0.00375	CcSEcCtD
Methamphetamine—Insomnia—Simvastatin—coronary artery disease	0.000265	0.00375	CcSEcCtD
Methamphetamine—Dyspepsia—Eplerenone—coronary artery disease	0.000265	0.00374	CcSEcCtD
Methamphetamine—Hypersensitivity—Acetylsalicylic acid—coronary artery disease	0.000265	0.00374	CcSEcCtD
Methamphetamine—Headache—Gemfibrozil—coronary artery disease	0.000263	0.00372	CcSEcCtD
Methamphetamine—Benzyl alcohol—ALDH2—coronary artery disease	0.000263	0.0893	CrCbGaD
Methamphetamine—Constipation—Ezetimibe—coronary artery disease	0.000263	0.00372	CcSEcCtD
Methamphetamine—Tachycardia—Niacin—coronary artery disease	0.000263	0.00371	CcSEcCtD
Methamphetamine—Agitation—Furosemide—coronary artery disease	0.000261	0.00369	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Eplerenone—coronary artery disease	0.00026	0.00367	CcSEcCtD
Methamphetamine—Palpitations—Perindopril—coronary artery disease	0.000258	0.00365	CcSEcCtD
Methamphetamine—Dyspepsia—Simvastatin—coronary artery disease	0.000258	0.00365	CcSEcCtD
Methamphetamine—Headache—Ticagrelor—coronary artery disease	0.000257	0.00364	CcSEcCtD
Methamphetamine—Constipation—Eplerenone—coronary artery disease	0.000257	0.00364	CcSEcCtD
Methamphetamine—Tremor—Losartan—coronary artery disease	0.000257	0.00363	CcSEcCtD
Methamphetamine—MAOA—cardiac ventricle—coronary artery disease	0.000257	0.0361	CbGeAlD
Methamphetamine—Urticaria—Fenofibrate—coronary artery disease	0.000255	0.0036	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Simvastatin—coronary artery disease	0.000253	0.00358	CcSEcCtD
Methamphetamine—Diarrhoea—Rosuvastatin—coronary artery disease	0.000253	0.00358	CcSEcCtD
Methamphetamine—Agitation—Losartan—coronary artery disease	0.000252	0.00356	CcSEcCtD
Methamphetamine—Tachycardia—Trandolapril—coronary artery disease	0.000251	0.00355	CcSEcCtD
Methamphetamine—Constipation—Simvastatin—coronary artery disease	0.000251	0.00354	CcSEcCtD
Methamphetamine—Urticaria—Clopidogrel—coronary artery disease	0.000251	0.00354	CcSEcCtD
Methamphetamine—Insomnia—Valsartan—coronary artery disease	0.00025	0.00354	CcSEcCtD
Methamphetamine—Tachycardia—Enalapril—coronary artery disease	0.00025	0.00354	CcSEcCtD
Methamphetamine—Insomnia—Olmesartan—coronary artery disease	0.000249	0.00352	CcSEcCtD
Methamphetamine—Urticaria—Lovastatin—coronary artery disease	0.000249	0.00352	CcSEcCtD
Methamphetamine—ADRA2C—cardiac ventricle—coronary artery disease	0.000247	0.0347	CbGeAlD
Methamphetamine—Tachycardia—Telmisartan—coronary artery disease	0.000247	0.00349	CcSEcCtD
Methamphetamine—Diarrhoea—Acetylsalicylic acid—coronary artery disease	0.000246	0.00347	CcSEcCtD
Methamphetamine—Dizziness—Rosuvastatin—coronary artery disease	0.000245	0.00346	CcSEcCtD
Methamphetamine—Urticaria—Ezetimibe—coronary artery disease	0.000244	0.00345	CcSEcCtD
Methamphetamine—Dyspepsia—Valsartan—coronary artery disease	0.000244	0.00344	CcSEcCtD
Methamphetamine—Insomnia—Niacin—coronary artery disease	0.000243	0.00344	CcSEcCtD
Methamphetamine—Dyspepsia—Olmesartan—coronary artery disease	0.000242	0.00343	CcSEcCtD
Methamphetamine—Palpitations—Losartan—coronary artery disease	0.000242	0.00343	CcSEcCtD
Methamphetamine—MAOA—myocardium—coronary artery disease	0.000241	0.0339	CbGeAlD
Methamphetamine—Tachycardia—Captopril—coronary artery disease	0.00024	0.00339	CcSEcCtD
Methamphetamine—Insomnia—Pravastatin—coronary artery disease	0.00024	0.00339	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Valsartan—coronary artery disease	0.000239	0.00338	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Olmesartan—coronary artery disease	0.000238	0.00336	CcSEcCtD
Methamphetamine—Dizziness—Acetylsalicylic acid—coronary artery disease	0.000238	0.00336	CcSEcCtD
Methamphetamine—Dyspepsia—Niacin—coronary artery disease	0.000237	0.00335	CcSEcCtD
Methamphetamine—Constipation—Valsartan—coronary artery disease	0.000237	0.00335	CcSEcCtD
Methamphetamine—Hypersensitivity—Fenofibrate—coronary artery disease	0.000236	0.00334	CcSEcCtD
Methamphetamine—SLC22A5—cardiac ventricle—coronary artery disease	0.000236	0.0332	CbGeAlD
Methamphetamine—Constipation—Olmesartan—coronary artery disease	0.000236	0.00333	CcSEcCtD
Methamphetamine—Dyspepsia—Pravastatin—coronary artery disease	0.000233	0.0033	CcSEcCtD
Methamphetamine—Tachycardia—Perindopril—coronary artery disease	0.000233	0.00329	CcSEcCtD
Methamphetamine—Urticaria—Simvastatin—coronary artery disease	0.000233	0.00329	CcSEcCtD
Methamphetamine—Insomnia—Trandolapril—coronary artery disease	0.000233	0.00329	CcSEcCtD
Methamphetamine—Hypersensitivity—Clopidogrel—coronary artery disease	0.000232	0.00329	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Niacin—coronary artery disease	0.000232	0.00328	CcSEcCtD
Methamphetamine—ADRA2C—myocardium—coronary artery disease	0.000232	0.0326	CbGeAlD
Methamphetamine—Insomnia—Enalapril—coronary artery disease	0.000232	0.00328	CcSEcCtD
Methamphetamine—Headache—Rosuvastatin—coronary artery disease	0.000232	0.00327	CcSEcCtD
Methamphetamine—Hypersensitivity—Lovastatin—coronary artery disease	0.000231	0.00326	CcSEcCtD
Methamphetamine—Insomnia—Telmisartan—coronary artery disease	0.000229	0.00323	CcSEcCtD
Methamphetamine—Constipation—Pravastatin—coronary artery disease	0.000227	0.0032	CcSEcCtD
Methamphetamine—Dyspepsia—Trandolapril—coronary artery disease	0.000227	0.0032	CcSEcCtD
Methamphetamine—Hypersensitivity—Ezetimibe—coronary artery disease	0.000226	0.0032	CcSEcCtD
Methamphetamine—Dyspepsia—Enalapril—coronary artery disease	0.000226	0.00319	CcSEcCtD
Methamphetamine—SLC18A2—blood—coronary artery disease	0.000224	0.0314	CbGeAlD
Methamphetamine—Dyspepsia—Telmisartan—coronary artery disease	0.000223	0.00315	CcSEcCtD
Methamphetamine—SLC22A5—myocardium—coronary artery disease	0.000222	0.0313	CbGeAlD
Methamphetamine—Insomnia—Captopril—coronary artery disease	0.000222	0.00314	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Trandolapril—coronary artery disease	0.000222	0.00314	CcSEcCtD
Methamphetamine—Tremor—Ramipril—coronary artery disease	0.00022	0.00312	CcSEcCtD
Methamphetamine—Constipation—Trandolapril—coronary artery disease	0.00022	0.00311	CcSEcCtD
Methamphetamine—Urticaria—Valsartan—coronary artery disease	0.00022	0.00311	CcSEcCtD
Methamphetamine—Diarrhoea—Fenofibrate—coronary artery disease	0.00022	0.0031	CcSEcCtD
Methamphetamine—Constipation—Enalapril—coronary artery disease	0.000219	0.0031	CcSEcCtD
Methamphetamine—Urticaria—Olmesartan—coronary artery disease	0.000219	0.00309	CcSEcCtD
Methamphetamine—Tachycardia—Losartan—coronary artery disease	0.000218	0.00309	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Telmisartan—coronary artery disease	0.000218	0.00309	CcSEcCtD
Methamphetamine—Dyspepsia—Captopril—coronary artery disease	0.000216	0.00306	CcSEcCtD
Methamphetamine—Constipation—Telmisartan—coronary artery disease	0.000216	0.00306	CcSEcCtD
Methamphetamine—Agitation—Ramipril—coronary artery disease	0.000216	0.00306	CcSEcCtD
Methamphetamine—Hypersensitivity—Simvastatin—coronary artery disease	0.000216	0.00305	CcSEcCtD
Methamphetamine—Insomnia—Perindopril—coronary artery disease	0.000216	0.00305	CcSEcCtD
Methamphetamine—Diarrhoea—Clopidogrel—coronary artery disease	0.000216	0.00305	CcSEcCtD
Methamphetamine—Diarrhoea—Lovastatin—coronary artery disease	0.000214	0.00303	CcSEcCtD
Methamphetamine—Urticaria—Niacin—coronary artery disease	0.000214	0.00302	CcSEcCtD
Methamphetamine—Dizziness—Fenofibrate—coronary artery disease	0.000212	0.003	CcSEcCtD
Methamphetamine—Urticaria—Pravastatin—coronary artery disease	0.000211	0.00298	CcSEcCtD
Methamphetamine—Diarrhoea—Ezetimibe—coronary artery disease	0.00021	0.00297	CcSEcCtD
Methamphetamine—Constipation—Captopril—coronary artery disease	0.00021	0.00297	CcSEcCtD
Methamphetamine—Dyspepsia—Perindopril—coronary artery disease	0.00021	0.00297	CcSEcCtD
Methamphetamine—Dizziness—Clopidogrel—coronary artery disease	0.000209	0.00295	CcSEcCtD
Methamphetamine—Palpitations—Ramipril—coronary artery disease	0.000208	0.00294	CcSEcCtD
Methamphetamine—Dizziness—Lovastatin—coronary artery disease	0.000207	0.00293	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Perindopril—coronary artery disease	0.000206	0.00291	CcSEcCtD
Methamphetamine—Diarrhoea—Eplerenone—coronary artery disease	0.000206	0.00291	CcSEcCtD
Methamphetamine—Urticaria—Trandolapril—coronary artery disease	0.000204	0.00289	CcSEcCtD
Methamphetamine—Constipation—Perindopril—coronary artery disease	0.000204	0.00289	CcSEcCtD
Methamphetamine—Hypersensitivity—Valsartan—coronary artery disease	0.000204	0.00288	CcSEcCtD
Methamphetamine—Urticaria—Enalapril—coronary artery disease	0.000204	0.00288	CcSEcCtD
Methamphetamine—Dizziness—Ezetimibe—coronary artery disease	0.000203	0.00287	CcSEcCtD
Methamphetamine—Palpitations—Timolol—coronary artery disease	0.000203	0.00287	CcSEcCtD
Methamphetamine—Insomnia—Losartan—coronary artery disease	0.000202	0.00286	CcSEcCtD
Methamphetamine—Headache—Fenofibrate—coronary artery disease	0.000201	0.00284	CcSEcCtD
Methamphetamine—Urticaria—Telmisartan—coronary artery disease	0.000201	0.00284	CcSEcCtD
Methamphetamine—Diarrhoea—Simvastatin—coronary artery disease	0.000201	0.00284	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Furosemide—coronary artery disease	0.0002	0.00283	CcSEcCtD
Methamphetamine—Tremor—Lisinopril—coronary artery disease	0.0002	0.00283	CcSEcCtD
Methamphetamine—Dizziness—Eplerenone—coronary artery disease	0.000199	0.00281	CcSEcCtD
Methamphetamine—Constipation—Furosemide—coronary artery disease	0.000198	0.0028	CcSEcCtD
Methamphetamine—Hypersensitivity—Niacin—coronary artery disease	0.000198	0.0028	CcSEcCtD
Methamphetamine—Headache—Clopidogrel—coronary artery disease	0.000198	0.00279	CcSEcCtD
Methamphetamine—MAOB—heart—coronary artery disease	0.000198	0.0278	CbGeAlD
Methamphetamine—Dyspepsia—Losartan—coronary artery disease	0.000197	0.00279	CcSEcCtD
Methamphetamine—Headache—Lovastatin—coronary artery disease	0.000196	0.00278	CcSEcCtD
Methamphetamine—Hypersensitivity—Pravastatin—coronary artery disease	0.000195	0.00276	CcSEcCtD
Methamphetamine—Dizziness—Simvastatin—coronary artery disease	0.000194	0.00274	CcSEcCtD
Methamphetamine—Headache—Ezetimibe—coronary artery disease	0.000193	0.00272	CcSEcCtD
Methamphetamine—Constipation—Losartan—coronary artery disease	0.000191	0.00271	CcSEcCtD
Methamphetamine—Urticaria—Perindopril—coronary artery disease	0.00019	0.00268	CcSEcCtD
Methamphetamine—Hypersensitivity—Trandolapril—coronary artery disease	0.00019	0.00268	CcSEcCtD
Methamphetamine—Diarrhoea—Valsartan—coronary artery disease	0.000189	0.00268	CcSEcCtD
Methamphetamine—Hypersensitivity—Enalapril—coronary artery disease	0.000189	0.00267	CcSEcCtD
Methamphetamine—Palpitations—Lisinopril—coronary artery disease	0.000189	0.00266	CcSEcCtD
Methamphetamine—Diarrhoea—Olmesartan—coronary artery disease	0.000188	0.00266	CcSEcCtD
Methamphetamine—Headache—Eplerenone—coronary artery disease	0.000188	0.00266	CcSEcCtD
Methamphetamine—Tachycardia—Ramipril—coronary artery disease	0.000187	0.00265	CcSEcCtD
Methamphetamine—MAOB—cardiovascular system—coronary artery disease	0.000186	0.0262	CbGeAlD
Methamphetamine—Hypersensitivity—Telmisartan—coronary artery disease	0.000186	0.00263	CcSEcCtD
Methamphetamine—Urticaria—Furosemide—coronary artery disease	0.000184	0.00261	CcSEcCtD
Methamphetamine—Diarrhoea—Niacin—coronary artery disease	0.000184	0.0026	CcSEcCtD
Methamphetamine—Headache—Simvastatin—coronary artery disease	0.000184	0.0026	CcSEcCtD
Methamphetamine—Dizziness—Valsartan—coronary artery disease	0.000183	0.00259	CcSEcCtD
Methamphetamine—Dizziness—Olmesartan—coronary artery disease	0.000182	0.00258	CcSEcCtD
Methamphetamine—Diarrhoea—Pravastatin—coronary artery disease	0.000181	0.00256	CcSEcCtD
Methamphetamine—Dizziness—Niacin—coronary artery disease	0.000178	0.00252	CcSEcCtD
Methamphetamine—Urticaria—Losartan—coronary artery disease	0.000178	0.00251	CcSEcCtD
Methamphetamine—Diarrhoea—Trandolapril—coronary artery disease	0.000176	0.00249	CcSEcCtD
Methamphetamine—Diarrhoea—Enalapril—coronary artery disease	0.000175	0.00248	CcSEcCtD
Methamphetamine—Dizziness—Pravastatin—coronary artery disease	0.000175	0.00248	CcSEcCtD
Methamphetamine—Insomnia—Ramipril—coronary artery disease	0.000174	0.00245	CcSEcCtD
Methamphetamine—Headache—Valsartan—coronary artery disease	0.000173	0.00245	CcSEcCtD
Methamphetamine—Diarrhoea—Telmisartan—coronary artery disease	0.000173	0.00245	CcSEcCtD
Methamphetamine—Headache—Olmesartan—coronary artery disease	0.000173	0.00244	CcSEcCtD
Methamphetamine—Hypersensitivity—Furosemide—coronary artery disease	0.000171	0.00242	CcSEcCtD
Methamphetamine—Dizziness—Trandolapril—coronary artery disease	0.00017	0.00241	CcSEcCtD
Methamphetamine—Tachycardia—Lisinopril—coronary artery disease	0.00017	0.0024	CcSEcCtD
Methamphetamine—Insomnia—Timolol—coronary artery disease	0.00017	0.0024	CcSEcCtD
Methamphetamine—Dizziness—Enalapril—coronary artery disease	0.000169	0.0024	CcSEcCtD
Methamphetamine—Dyspepsia—Ramipril—coronary artery disease	0.000169	0.00239	CcSEcCtD
Methamphetamine—MAOB—cardiac atrium—coronary artery disease	0.000169	0.0238	CbGeAlD
Methamphetamine—Headache—Niacin—coronary artery disease	0.000169	0.00238	CcSEcCtD
Methamphetamine—MAOA—heart—coronary artery disease	0.000169	0.0237	CbGeAlD
Methamphetamine—Diarrhoea—Captopril—coronary artery disease	0.000168	0.00238	CcSEcCtD
Methamphetamine—Dizziness—Telmisartan—coronary artery disease	0.000167	0.00236	CcSEcCtD
Methamphetamine—Headache—Pravastatin—coronary artery disease	0.000166	0.00235	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Ramipril—coronary artery disease	0.000166	0.00234	CcSEcCtD
Methamphetamine—Dyspepsia—Timolol—coronary artery disease	0.000165	0.00234	CcSEcCtD
Methamphetamine—Hypersensitivity—Losartan—coronary artery disease	0.000165	0.00233	CcSEcCtD
Methamphetamine—Constipation—Ramipril—coronary artery disease	0.000164	0.00232	CcSEcCtD
Methamphetamine—Diarrhoea—Perindopril—coronary artery disease	0.000163	0.00231	CcSEcCtD
Methamphetamine—Dizziness—Captopril—coronary artery disease	0.000163	0.0023	CcSEcCtD
Methamphetamine—ADRA2C—heart—coronary artery disease	0.000162	0.0228	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Timolol—coronary artery disease	0.000162	0.00229	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP2C19—coronary artery disease	0.000161	0.0548	CrCbGaD
Methamphetamine—Headache—Trandolapril—coronary artery disease	0.000161	0.00228	CcSEcCtD
Methamphetamine—Headache—Enalapril—coronary artery disease	0.000161	0.00227	CcSEcCtD
Methamphetamine—MAOA—cardiovascular system—coronary artery disease	0.000159	0.0224	CbGeAlD
Methamphetamine—Diarrhoea—Furosemide—coronary artery disease	0.000159	0.00224	CcSEcCtD
Methamphetamine—Headache—Telmisartan—coronary artery disease	0.000158	0.00224	CcSEcCtD
Methamphetamine—Dizziness—Perindopril—coronary artery disease	0.000158	0.00223	CcSEcCtD
Methamphetamine—Insomnia—Lisinopril—coronary artery disease	0.000157	0.00223	CcSEcCtD
Methamphetamine—SLC22A5—heart—coronary artery disease	0.000155	0.0218	CbGeAlD
Methamphetamine—SLC6A4—blood—coronary artery disease	0.000155	0.0218	CbGeAlD
Methamphetamine—Headache—Captopril—coronary artery disease	0.000154	0.00218	CcSEcCtD
Methamphetamine—Dizziness—Furosemide—coronary artery disease	0.000153	0.00217	CcSEcCtD
Methamphetamine—Dyspepsia—Lisinopril—coronary artery disease	0.000153	0.00217	CcSEcCtD
Methamphetamine—Diarrhoea—Losartan—coronary artery disease	0.000153	0.00217	CcSEcCtD
Methamphetamine—Urticaria—Ramipril—coronary artery disease	0.000152	0.00216	CcSEcCtD
Methamphetamine—Amphetamine—SLC22A3—coronary artery disease	0.000152	0.0515	CrCbGaD
Methamphetamine—Gastrointestinal disorder—Lisinopril—coronary artery disease	0.00015	0.00212	CcSEcCtD
Methamphetamine—Headache—Perindopril—coronary artery disease	0.00015	0.00211	CcSEcCtD
Methamphetamine—Urticaria—Timolol—coronary artery disease	0.000149	0.00211	CcSEcCtD
Methamphetamine—Constipation—Lisinopril—coronary artery disease	0.000149	0.0021	CcSEcCtD
Methamphetamine—Dizziness—Losartan—coronary artery disease	0.000148	0.00209	CcSEcCtD
Methamphetamine—MAOB—blood—coronary artery disease	0.000147	0.0207	CbGeAlD
Methamphetamine—Headache—Furosemide—coronary artery disease	0.000145	0.00205	CcSEcCtD
Methamphetamine—MAOA—cardiac atrium—coronary artery disease	0.000144	0.0203	CbGeAlD
Methamphetamine—Hypersensitivity—Ramipril—coronary artery disease	0.000141	0.002	CcSEcCtD
Methamphetamine—Headache—Losartan—coronary artery disease	0.00014	0.00198	CcSEcCtD
Methamphetamine—ADRA2C—cardiac atrium—coronary artery disease	0.000139	0.0195	CbGeAlD
Methamphetamine—Urticaria—Lisinopril—coronary artery disease	0.000138	0.00196	CcSEcCtD
Methamphetamine—Hypersensitivity—Timolol—coronary artery disease	0.000138	0.00195	CcSEcCtD
Methamphetamine—SLC22A5—cardiac atrium—coronary artery disease	0.000133	0.0187	CbGeAlD
Methamphetamine—Diarrhoea—Ramipril—coronary artery disease	0.000131	0.00186	CcSEcCtD
Methamphetamine—ADRA2A—heart—coronary artery disease	0.000129	0.0182	CbGeAlD
Methamphetamine—Diarrhoea—Timolol—coronary artery disease	0.000128	0.00182	CcSEcCtD
Methamphetamine—Hypersensitivity—Lisinopril—coronary artery disease	0.000128	0.00181	CcSEcCtD
Methamphetamine—Dizziness—Ramipril—coronary artery disease	0.000127	0.00179	CcSEcCtD
Methamphetamine—MAOA—blood—coronary artery disease	0.000126	0.0177	CbGeAlD
Methamphetamine—Dizziness—Timolol—coronary artery disease	0.000124	0.00175	CcSEcCtD
Methamphetamine—ADRA2C—blood—coronary artery disease	0.000121	0.017	CbGeAlD
Methamphetamine—Phenylpropanolamine—ADRB1—coronary artery disease	0.00012	0.0409	CrCbGaD
Methamphetamine—Headache—Ramipril—coronary artery disease	0.00012	0.0017	CcSEcCtD
Methamphetamine—Diarrhoea—Lisinopril—coronary artery disease	0.000119	0.00168	CcSEcCtD
Methamphetamine—Headache—Timolol—coronary artery disease	0.000118	0.00166	CcSEcCtD
Methamphetamine—SLC22A5—blood—coronary artery disease	0.000116	0.0163	CbGeAlD
Methamphetamine—Dizziness—Lisinopril—coronary artery disease	0.000115	0.00163	CcSEcCtD
Methamphetamine—Ephedrine—ADRB2—coronary artery disease	0.000113	0.0383	CrCbGaD
Methamphetamine—ADRA2A—cardiac atrium—coronary artery disease	0.000111	0.0155	CbGeAlD
Methamphetamine—Headache—Lisinopril—coronary artery disease	0.000109	0.00154	CcSEcCtD
Methamphetamine—Pseudoephedrine—ADRB1—coronary artery disease	0.000102	0.0345	CrCbGaD
Methamphetamine—Phenylpropanolamine—ADRB2—coronary artery disease	0.000101	0.0344	CrCbGaD
Methamphetamine—Pseudoephedrine—TNF—coronary artery disease	9.65e-05	0.0328	CrCbGaD
Methamphetamine—ADRA2A—blood—coronary artery disease	9.65e-05	0.0136	CbGeAlD
Methamphetamine—Nateglinide—PPARG—coronary artery disease	9.47e-05	0.0322	CrCbGaD
Methamphetamine—Pseudoephedrine—ADRB2—coronary artery disease	8.55e-05	0.0291	CrCbGaD
Methamphetamine—CYP2D6—blood—coronary artery disease	7.47e-05	0.0105	CbGeAlD
Methamphetamine—Selegiline—CYP2C19—coronary artery disease	7.19e-05	0.0244	CrCbGaD
Methamphetamine—Phenelzine—CYP2C19—coronary artery disease	6.33e-05	0.0215	CrCbGaD
Methamphetamine—Nateglinide—ALB—coronary artery disease	3.56e-05	0.0121	CrCbGaD
Methamphetamine—ADRA2C—Signaling by GPCR—JAK2—coronary artery disease	2.88e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOC3—coronary artery disease	2.87e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EDN1—coronary artery disease	2.87e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LDLR—coronary artery disease	2.85e-06	3.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AGT—coronary artery disease	2.85e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL5—coronary artery disease	2.85e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOB—coronary artery disease	2.83e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC9A1—coronary artery disease	2.82e-06	3.02e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTT1—coronary artery disease	2.82e-06	3.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—coronary artery disease	2.81e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CSF2—coronary artery disease	2.81e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGF1—coronary artery disease	2.81e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PPP2CA—coronary artery disease	2.8e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOE—coronary artery disease	2.79e-06	2.99e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CETP—coronary artery disease	2.79e-06	2.99e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GCLC—coronary artery disease	2.79e-06	2.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LPL—coronary artery disease	2.78e-06	2.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ITGAV—coronary artery disease	2.77e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TGFB1—coronary artery disease	2.77e-06	2.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KNG1—coronary artery disease	2.77e-06	2.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RPS6KB1—coronary artery disease	2.76e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MEF2C—coronary artery disease	2.76e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—APOA1—coronary artery disease	2.76e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—POMC—coronary artery disease	2.76e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CREB1—coronary artery disease	2.76e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—coronary artery disease	2.76e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SDC1—coronary artery disease	2.76e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AGTR1—coronary artery disease	2.75e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PRKCD—coronary artery disease	2.75e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—MAPK1—coronary artery disease	2.72e-06	2.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—LPL—coronary artery disease	2.71e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL2—coronary artery disease	2.7e-06	2.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6R—coronary artery disease	2.69e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ITGB3—coronary artery disease	2.69e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR2A—coronary artery disease	2.69e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL10—coronary artery disease	2.69e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—C3—coronary artery disease	2.68e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PLG—coronary artery disease	2.68e-06	2.87e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ALB—coronary artery disease	2.66e-06	2.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GPX1—coronary artery disease	2.64e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—coronary artery disease	2.63e-06	2.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PPP2CA—coronary artery disease	2.61e-06	2.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRB2—coronary artery disease	2.61e-06	2.8e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PSMA6—coronary artery disease	2.6e-06	2.79e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PSMB5—coronary artery disease	2.6e-06	2.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PRKCE—coronary artery disease	2.58e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—JAK2—coronary artery disease	2.57e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CD36—coronary artery disease	2.57e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SOCS1—coronary artery disease	2.57e-06	2.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PRKCD—coronary artery disease	2.57e-06	2.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—S100B—coronary artery disease	2.56e-06	2.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HIF1A—coronary artery disease	2.56e-06	2.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AGT—coronary artery disease	2.55e-06	2.73e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CTGF—coronary artery disease	2.54e-06	2.73e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NOS3—coronary artery disease	2.54e-06	2.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT1—coronary artery disease	2.54e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPP2CA—coronary artery disease	2.54e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SOCS3—coronary artery disease	2.54e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMGCR—coronary artery disease	2.52e-06	2.7e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GOT2—coronary artery disease	2.52e-06	2.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR2A—coronary artery disease	2.51e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFBR2—coronary artery disease	2.51e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KITLG—coronary artery disease	2.51e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—C3—coronary artery disease	2.51e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LEP—coronary artery disease	2.5e-06	2.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOE—coronary artery disease	2.5e-06	2.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APOA1—coronary artery disease	2.47e-06	2.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT5A—coronary artery disease	2.45e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP3—coronary artery disease	2.45e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KDR—coronary artery disease	2.45e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—coronary artery disease	2.44e-06	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK14—coronary artery disease	2.43e-06	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PPARG—coronary artery disease	2.43e-06	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—POMC—coronary artery disease	2.4e-06	2.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HIF1A—coronary artery disease	2.39e-06	2.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ESR1—coronary artery disease	2.39e-06	2.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AGT—coronary artery disease	2.38e-06	2.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—coronary artery disease	2.37e-06	2.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOB—coronary artery disease	2.37e-06	2.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PIK3CA—coronary artery disease	2.36e-06	2.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—F2—coronary artery disease	2.36e-06	2.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FN1—coronary artery disease	2.36e-06	2.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—coronary artery disease	2.35e-06	2.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6ST—coronary artery disease	2.35e-06	2.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—JAK2—coronary artery disease	2.34e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—coronary artery disease	2.33e-06	2.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOE—coronary artery disease	2.33e-06	2.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EDN1—coronary artery disease	2.33e-06	2.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKBIA—coronary artery disease	2.33e-06	2.5e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—coronary artery disease	2.33e-06	2.49e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PLCB1—coronary artery disease	2.32e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AGT—coronary artery disease	2.31e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL5—coronary artery disease	2.31e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APOA1—coronary artery disease	2.31e-06	2.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KDR—coronary artery disease	2.29e-06	2.45e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CA—coronary artery disease	2.28e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CSF2—coronary artery disease	2.28e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF1—coronary artery disease	2.28e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK14—coronary artery disease	2.27e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOE—coronary artery disease	2.27e-06	2.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LPL—coronary artery disease	2.26e-06	2.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KIT—coronary artery disease	2.26e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCA1—coronary artery disease	2.25e-06	2.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RPS6KB1—coronary artery disease	2.24e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MEF2C—coronary artery disease	2.24e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—APOA1—coronary artery disease	2.24e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ESR1—coronary artery disease	2.23e-06	2.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—F2—coronary artery disease	2.2e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FN1—coronary artery disease	2.2e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6ST—coronary artery disease	2.19e-06	2.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—coronary artery disease	2.19e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ITGB3—coronary artery disease	2.18e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GGT1—coronary artery disease	2.18e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GOT1—coronary artery disease	2.18e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKBIA—coronary artery disease	2.18e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GSK3B—coronary artery disease	2.16e-06	2.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—POMC—coronary artery disease	2.15e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CREB1—coronary artery disease	2.15e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—coronary artery disease	2.13e-06	2.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PPP2CA—coronary artery disease	2.12e-06	2.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KIT—coronary artery disease	2.11e-06	2.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL2—coronary artery disease	2.1e-06	2.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6R—coronary artery disease	2.09e-06	2.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NOS3—coronary artery disease	2.09e-06	2.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PRKCD—coronary artery disease	2.08e-06	2.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—coronary artery disease	2.07e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—MAPK1—coronary artery disease	2.06e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR2A—coronary artery disease	2.04e-06	2.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—C3—coronary artery disease	2.04e-06	2.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GSK3B—coronary artery disease	2.02e-06	2.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CREB1—coronary artery disease	2.01e-06	2.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—POMC—coronary artery disease	2.01e-06	2.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARG—coronary artery disease	1.98e-06	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CA—coronary artery disease	1.96e-06	2.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL2—coronary artery disease	1.96e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SERPINE1—coronary artery disease	1.96e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6R—coronary artery disease	1.96e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—coronary artery disease	1.95e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—POMC—coronary artery disease	1.95e-06	2.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HIF1A—coronary artery disease	1.94e-06	2.08e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	1.94e-06	2.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AGT—coronary artery disease	1.94e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CA—coronary artery disease	1.93e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—coronary artery disease	1.93e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMOX1—coronary artery disease	1.93e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—coronary artery disease	1.93e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—MAPK1—coronary artery disease	1.92e-06	2.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—coronary artery disease	1.91e-06	2.05e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAT—coronary artery disease	1.9e-06	2.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGF2—coronary artery disease	1.9e-06	2.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOE—coronary artery disease	1.9e-06	2.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—coronary artery disease	1.9e-06	2.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APOA1—coronary artery disease	1.87e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOS3—coronary artery disease	1.87e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—coronary artery disease	1.86e-06	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KDR—coronary artery disease	1.86e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOB—coronary artery disease	1.85e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK14—coronary artery disease	1.85e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CA—coronary artery disease	1.83e-06	1.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SERPINE1—coronary artery disease	1.83e-06	1.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JAK2—coronary artery disease	1.82e-06	1.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ESR1—coronary artery disease	1.81e-06	1.94e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—coronary artery disease	1.8e-06	1.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FN1—coronary artery disease	1.79e-06	1.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—F2—coronary artery disease	1.79e-06	1.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CA—coronary artery disease	1.78e-06	1.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6ST—coronary artery disease	1.78e-06	1.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—coronary artery disease	1.78e-06	1.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGF2—coronary artery disease	1.77e-06	1.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKBIA—coronary artery disease	1.77e-06	1.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LPL—coronary artery disease	1.76e-06	1.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOS3—coronary artery disease	1.75e-06	1.88e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX1—coronary artery disease	1.72e-06	1.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KIT—coronary artery disease	1.71e-06	1.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JAK2—coronary artery disease	1.7e-06	1.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NOS3—coronary artery disease	1.7e-06	1.82e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CD36—coronary artery disease	1.67e-06	1.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CA—coronary artery disease	1.67e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—coronary artery disease	1.66e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPP2CA—coronary artery disease	1.65e-06	1.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GSK3B—coronary artery disease	1.64e-06	1.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—POMC—coronary artery disease	1.63e-06	1.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CREB1—coronary artery disease	1.63e-06	1.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—coronary artery disease	1.6e-06	1.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL2—coronary artery disease	1.59e-06	1.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—coronary artery disease	1.59e-06	1.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6R—coronary artery disease	1.59e-06	1.7e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—coronary artery disease	1.59e-06	1.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—coronary artery disease	1.58e-06	1.69e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—coronary artery disease	1.58e-06	1.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—coronary artery disease	1.57e-06	1.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAPK1—coronary artery disease	1.56e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—coronary artery disease	1.55e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—coronary artery disease	1.55e-06	1.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—coronary artery disease	1.55e-06	1.66e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AGT—coronary artery disease	1.51e-06	1.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—coronary artery disease	1.5e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—coronary artery disease	1.5e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CA—coronary artery disease	1.49e-06	1.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SERPINE1—coronary artery disease	1.49e-06	1.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—coronary artery disease	1.48e-06	1.59e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOE—coronary artery disease	1.48e-06	1.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—coronary artery disease	1.48e-06	1.58e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APOA1—coronary artery disease	1.46e-06	1.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—coronary artery disease	1.46e-06	1.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—coronary artery disease	1.45e-06	1.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF2—coronary artery disease	1.44e-06	1.54e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CA—coronary artery disease	1.43e-06	1.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOS3—coronary artery disease	1.42e-06	1.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—coronary artery disease	1.4e-06	1.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JAK2—coronary artery disease	1.38e-06	1.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—coronary artery disease	1.36e-06	1.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CA—coronary artery disease	1.35e-06	1.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—coronary artery disease	1.35e-06	1.45e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARG—coronary artery disease	1.29e-06	1.38e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—POMC—coronary artery disease	1.27e-06	1.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—coronary artery disease	1.26e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—coronary artery disease	1.26e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFB1—coronary artery disease	1.24e-06	1.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—coronary artery disease	1.22e-06	1.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK1—coronary artery disease	1.21e-06	1.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—coronary artery disease	1.21e-06	1.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—coronary artery disease	1.2e-06	1.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CA—coronary artery disease	1.18e-06	1.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—coronary artery disease	1.17e-06	1.26e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—coronary artery disease	1.17e-06	1.25e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—coronary artery disease	1.16e-06	1.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFB1—coronary artery disease	1.16e-06	1.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—coronary artery disease	1.14e-06	1.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK1—coronary artery disease	1.13e-06	1.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NOS3—coronary artery disease	1.11e-06	1.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—coronary artery disease	1.11e-06	1.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CA—coronary artery disease	1.05e-06	1.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—coronary artery disease	1.02e-06	1.1e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—coronary artery disease	1.01e-06	1.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CA—coronary artery disease	9.84e-07	1.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—coronary artery disease	9.61e-07	1.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CA—coronary artery disease	9.56e-07	1.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFB1—coronary artery disease	9.39e-07	1.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—coronary artery disease	9.33e-07	1e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK1—coronary artery disease	9.21e-07	9.88e-06	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—coronary artery disease	8.71e-07	9.34e-06	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—coronary artery disease	8.61e-07	9.23e-06	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—coronary artery disease	8.04e-07	8.62e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CA—coronary artery disease	7.99e-07	8.57e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—coronary artery disease	7.81e-07	8.37e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—coronary artery disease	7.08e-07	7.59e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—coronary artery disease	6.53e-07	7e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CA—coronary artery disease	6.23e-07	6.68e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—coronary artery disease	5.09e-07	5.46e-06	CbGpPWpGaD
